Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-cash Items (2023 - 2025)

Historic Non-cash Items for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $15.5 million.

  • Compass Therapeutics' Non-cash Items rose 2916.67% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 2916.67%. This contributed to the annual value of $579000.0 for FY2024, which is 516363.64% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Non-cash Items is $15.5 million, which was up 2916.67% from $19.5 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Non-cash Items registered a high of $21.5 million during Q1 2025, and its lowest value of $11000.0 during Q4 2023.
  • Its 3-year average for Non-cash Items is $11.5 million, with a median of $11.7 million in 2024.
  • The largest annual percentage gain for Compass Therapeutics' Non-cash Items in the last 5 years was 516363.64% (2024), contrasted with its biggest fall of 88.5% (2024).
  • Compass Therapeutics' Non-cash Items (Quarter) stood at $11000.0 in 2023, then soared by 5163.64% to $579000.0 in 2024, then soared by 2577.03% to $15.5 million in 2025.
  • Its last three reported values are $15.5 million in Q3 2025, $19.5 million for Q2 2025, and $21.5 million during Q1 2025.